Home Newsfeeds Raymond James Downgrades Lakeland Bancorp to Outperform, Lowers Price Target to $17

Raymond James Downgrades Lakeland Bancorp to Outperform, Lowers Price Target to $17

Raymond James analyst William Wallace downgrades Lakeland Bancorp (NASDAQ:LBAI) from Strong Buy to Outperform and lowers the price target from $20 to $17.

byBenzinga Newsdesk

July 7, 2022

1 minute read

Raymond James analyst William Wallace downgrades Lakeland Bancorp (NASDAQ:LBAI) from Strong Buy to Outperform and lowers the price target from $20 to $17.

Why Is CarLotz Higher By More Than 30%: Here Are 28 Stocks Moving Premarket

By Lisa Levin

August 10, 6:08 AM

Gainers ObsEva SA (NASDAQ: OBSV) shares rose 33.8% to $0.4080 in pre-market trading. ObsEva recently announced a $31 million debt retirement and $11 million debt refinancing.

ABCL

News

Mogo Extends Innovative Marketing Agreement With Postmedia To End Of 2024

By Happy Mohamed

August 11, 2:15 PM

Mogo Inc. (TSX:MOGO) (NASDAQ:MOGO) ("Mogo" or the "Company"), a digital payments and financial technology company, today announced that it has amended its marketing collaboration agreement with

MOGO

Avenue Therapeutics Buys Baergic Bio, Beefs Up Central Nervous System-Focused Portfolio

By Vandana Singh

November 8, 1:26 PM

Avenue Therapeutics Inc (NASDAQ:ATXI) acquired Baergic Bio Inc pursuant to the previously disclosed Share Contribution Agreement with its parent company, Fortress Biotech Inc (NASDAQ:FBIO).…

ATXI

Avantor Q4 Adjusted EPS $0.32 Beats $0.30 Estimate, Sales $1.79B Miss $1.80B Estimate

By Benzinga Newsdesk

February 3, 7:06 AM

Avantor (NYSE:AVTR) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.30 by 6.67 percent. This is a 11.11 percent decrease over earnings of $0.36 per share from the same

AVTR

Raymond James Downgrades Lakeland Bancorp to Outperform, Lowers Price Target to $17

Related Posts

Why Is CarLotz Higher By More Than 30%: Here Are 28 Stocks Moving Premarket

Mogo Extends Innovative Marketing Agreement With Postmedia To End Of 2024

Avenue Therapeutics Buys Baergic Bio, Beefs Up Central Nervous System-Focused Portfolio

Avantor Q4 Adjusted EPS $0.32 Beats $0.30 Estimate, Sales $1.79B Miss $1.80B Estimate